Wilmer Eye Institute receives $10 million donation from James and Heather Gills
October 3rd 2024The donation will support the development of the Artificial Intelligence Innovation Center, a collaborative hub with a focus of preserving the vision of patients with various eye conditions and eliminating blindness.
Harrow relaunches triamcinolone acetonide injectable suspension
October 3rd 2024Marketed as Triesence, it is a preservative free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.
EyeCon 2024: Collaborative care in light adjustable lenses creates better outcomes for patients
September 28th 2024A collaborative model not only enhances the post-cataract experience but also paves the way for a future where refractive outcomes are accessible to all, regardless of the surgeon's specialty.
EyeCon 2024: Residents honored with Visionary in Eye Care awards
September 28th 2024Three resident eye care providers—Anupam Garg, MD, PhD; Khanh Huang, OD; and Shail Patel, MD—were honored with the Visionary in Eye Care award at EyeCon 2024, which recognizes their achievements and contributions during their residency programs.
EyeCon 2024: New treatments in geographic atrophy from detection to intervention
September 28th 2024Adam S. Wenick, MD, PhD, chaired a symposium on geographic atrophy (GA) at EyeCon 2024, focusing on the diagnosis, monitoring, and FDA-approved treatments for GA. The session with Leonard Messner, OD, FAAO, also included case presentations that highlighted key factors for clinicians to consider when selecting appropriate treatment options.
EyeCon 2024: Key takeaways for enhanced patient care from Day 1
September 28th 2024Optometry cochairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, MA, FAAO, highlight the conference’s focus on collaboration, featuring topics like red flags for patient care, thyroid eye disease, and diabetes management.
Retina Society 2024: A comparison of tyrosine kinase inhibitors in development
September 26th 2024Sumit Sharma, MD, sat down with Sydney Crago of Modern Retina to discuss his presentation on the 3 tyrosine kinase inhibitors currently in development for the treatment of retina conditions at the Retina Society meeting being held this year in Lisbon, Portugal.